Chai Discovery has announced a strategic collaboration with Bristol Myers Squibb (BMS) to accelerate AI-powered antibody discovery, moving generative molecular design directly into active drug development workflows.
Under the agreement, Bristol Myers Squibb will leverage Chai Discovery’s advanced molecular folding and generative design models to identify novel antibody candidates across its therapeutic portfolio. The integration allows BMS to incorporate sophisticated generative AI into its early-stage discovery pipelines to target complex disease pathways.
Chai Discovery’s AI foundation models are engineered to generate de novo molecular structures based on defined target criteria. By predicting molecular folding and designing optimized candidates computationally, the technology significantly compresses discovery timelines while unlocking challenging biological targets that conventional drug discovery approaches have historically struggled to address.
By combining Chai’s cutting-edge computational capabilities with Bristol Myers Squibb’s extensive therapeutic expertise and clinical drug development infrastructure, the collaboration aims to pioneer breakthrough therapies and expedite the journey of next-generation antibody medicines into clinical trials.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
